BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
May 18 2023 - 8:30AM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”),
a global clinical-stage biopharmaceutical company focused on using
a groundbreaking technology platform for drug discovery and
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs, today announced that the
Company and Memorial Sloan Kettering Cancer Center (MSK) will
present a poster at the 2023 American Society of Clinical Oncology
(ASCO) Annual Meeting, taking place on June 2 through 6 in Chicago,
IL.
The poster, titled, “Plinabulin to shorten neutropenia and
improve quality of life peri-autologous hematopoietic cell
transplant,” will be presented by Dr. Gunjan Shah, MD, MS,
Assistant Attending Physician at MSKCC and Principal Investigator
of the BeyondSpring-MSKCC pilot trial evaluating Plinabulin in
combination with pegfilgrastim in multiple myeloma patients who
undergo an autologous hematopoietic cell transplant (AHCT).
Additional presentation details are as follows:
- Poster Session Date / Time: Monday, June 5,
2023, at 9 a.m. to 12 p.m. ET
- Location: McCormick Place Convention Center,
Hall A
- Track: Hematologic Malignancies
- Abstract / Poster Board No.: 8023 / 15
About BeyondSpring BeyondSpring (NASDAQ: BYSI)
is a global clinical-stage biopharmaceutical company focused on
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs. The Company is advancing
its first-in-class lead asset, Plinabulin, as a direct anti-cancer
agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly. Learn more by
visiting https://beyondspringpharma.com, and follow us on LinkedIn
and Twitter.
Investor Contact:IR@beyondspringpharma.com
Media Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Apr 2023 to Apr 2024